The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.
Long-Term Administration of Mifepristone (RU486): Clinical Tolerance During Extended Treatment of Meningioma
Abstract
BACKGROUND: Mifepristone (RU486) is an oral antiprogestational and, to a lesser extent, antiglucocorticoid agent commonly used for short-term (single-day) therapy. However, treatment of neoplasms or chronic conditions will require long-term administration. Meningioma is a benign central nervous system tumor that is often progesterone-but not estrogen-receptor positive, making long-term antiprogestational therapy a logical treatment strategy. METHODS: Patients with unresectable meningioma were treated with oral mifepristone 200 mg/day. This dose was selected to provide significant antiprogestational but not antiglucocorticoid activity. Patients also received oral dexamethasone 1 mg/day for the first 14 days. Serial follow-up allowed evaluation for tolerability and side effects of long-term therapy as well as observation for efficacy (tumor shrinkage or improvement in visual fields). RESULTS: Twenty-eight patients received daily oral mifepristone for a total of 1,626 patient-months of treatment. The median duration of therapy was 35 months (range 2-157 months). Repeated oral administration was well tolerated with mild fatigue (22 patients), hot flashes (13 patients), and gynecomastia/breast tenderness (6 patients) being the most common side effects. However, endometrial hyperplasia or polyps were documented in 3 patients and one patient developed peritoneal adenocarcinoma after 9 years of therapy. Minor responses (improved automated visual field examination or improved CT or MRI scan) were noted in 8 patients, 7 of whom were male or premenopausal female. CONCLUSIONS: Long-term administration of mifepristone is feasible and clinically well tolerated, with generally mild toxicity. However, endometrial hyperplasia was noted in several patients. In view of the association between long-term treatment with tamoxifen (another agent that can induce an unopposed estrogen effect) and endometrial cancer, this observation will require further investigation and screening. Minor regression of meningioma that can result in significant clinical benefit is suggested in the male and premenopausal female subgroups of patients.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Rapid Reversal of Psychotic Depression Using Mifepristone
Belanoff, J. K., Flores, B. H., Kalezhan, M., Sund, B., & Schatzberg, A. F. (2001) · Journal of Clinical Psychopharmacology · doi:10.1097/00004714-200110000-00009 · Cited by 282
Treatment of endometriosis with the antiprogesterone mifepristone (RU486)
Michael Kettel, L., Murphy, A. A., Morales, A. J., Ulmann, A., Baulieu, E. E., & Yen, S. S. C. (1996) · Fertility and Sterility · doi:10.1016/s0015-0282(16)58022-4 · Cited by 216
Cited by
Histological classification and molecular genetics of meningiomas
Riemenschneider, M. J., Perry, A., & Reifenberger, G. (2006) · The Lancet Neurology · doi:10.1016/s1474-4422(06)70625-1 · Cited by 573
Kaley, T., Barani, I., Chamberlain, M., McDermott, M., Panageas, K., Raizer, J., Rogers, L., Schiff, D., Vogelbaum, M., Weber, D., et al. (2014) · Neuro-Oncology · doi:10.1093/neuonc/not330 · Cited by 270
The timing of antidepressant effects: a comparison of diverse pharmacological and somatic treatments
Machado-Vieira, R., Baumann, J., Wheeler-Castillo, C., Latov, D., Henter, I. D., Salvadore, G., & Zarate, C. A. (2010) · Pharmaceuticals · doi:10.3390/ph3010019 · Cited by 263
Metadata
- Authors
- Grunberg, S. M., Weiss, M. H., Russell, C. A., Spitz, I. M., Ahmadi, J., Sadun, A., & Sitruk-Ware, R.
- Venue
- Cancer Investigation
- Publisher
- Informa UK Limited
- Published
- 2006-01
- Volume
- 24
- Issue
- 8
- Pages
- 727-733
- ISSN
- 0735-7907 (ISSN-L)
- 1532-4192
- OpenAlex
- W2118328286
- Cited by
- 183
- References
- 2
- FWCI
- 6.64
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Long-Term Administration of Mifepristone (RU486): Clinical Tolerance During Extended Treatment of Meningioma. https://app.cochat.ai/papers/10.1080/07357900601062339
- The paper
- Grunberg, S. M., Weiss, M. H., Russell, C. A., Spitz, I. M., Ahmadi, J., Sadun, A., & Sitruk-Ware, R. (2006). Long-Term Administration of Mifepristone (RU486): Clinical Tolerance During Extended Treatment of Meningioma. Cancer Investigation. https://doi.org/10.1080/07357900601062339
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.